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Abstract 
 
The inception of World Trade Organization (WTO) in 1995 was expected to reduce trade 
barriers across member countries on one hand and facilitate growth though promotion of 
international trade in merchandise products and services on the other. The subsequent WTO-led 
reforms deepened the globalization wave. In recent times however, the world is witnessing a phase 
of ‘de-globalization’, with rise in trade barriers and inwardness. The recent increase in US tariffs 
on Chinese exports and countermeasures imposed by China are a case in point. In 2014 India has 
initiated the Make-in-India scheme for deepening industrialization and facilitating exports. The 
current paper evaluates the possible opportunities for expanding Indian pharmaceutical exports in 
the US market, given the increase in tariff against Chinese products with the help of select trade 
indices. The analysis portrays a modest opportunity for Indian pharmaceutical exports in the US 
market, based on their past performance. Only six products at HS 6-digit level, based on the six 
indicators, are found to be enjoying competitiveness in the US market. The paper concludes that 
facilitating R&D in pharma segment as well as expanding the coverage of mutual recognition of 
standards in US may be explored as possible steps for enhancing Indian exports.  
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Recent US-China Tariff War: 
Opportunities for Indian Pharmaceutical Exports? 
 
1. Introduction 
 
The inception of World Trade Organization (WTO) in 1995 was expected to reduce trade 
barriers across member countries on one hand and facilitate growth though promotion of 
international trade in merchandise products and services on the other. The subsequent WTO-led 
reforms deepened the globalization wave in the next two decades. In recent times however, the 
world is witnessing a phase of ‘de-globalization’, with rise in trade barriers and inwardness (James, 
2017).  The backlash towards globalization can be explained by the undercurrent of several factors. 
First, slow progress of the Doha round of negotiations since 2001 have lowered the attraction of 
the multilateral trade reform process to a major extent. The deadlock at the multilateral forum 
occur primarily due to the differences between developed and developing countries over key 
reform agendas (Fergusson, 2011). Second, faster resolution of tariff and other non-tariff barriers 
(NTBs) reforms have enhanced the role of regional trade agreements (RTAs) as a trade-promotion 
route (Neufeld, 2014). It has further been noted that trade facilitation measures are instrumental in 
strengthening participation in Global Value Chains (GVCs) and International Production 
Networks (IPNs) (Shepherd, 2016). Hence over the last decade a number of RTAs have 
implemented trade facilitation measures, investment agreement, mutual recognition agreements 
(MRAs) on technical standards etc. within their fold (Horn et al., 2009). However, freer trade 
within the RTAs have lowered the incentive for countries to proactively commit at the WTO 
forums, and thereby threatened the multilateral negotiation process (Baldwin, 2014). Finally, the 
declining growth projections in the time of recession (IMF, 2018) has fueled the protectionist 
mindsets, in line with past trends (Baldwin and Evenett, 2009).  
 
Since 1995, the US has participated aggressively in the WTO negotiation process and often 
pushed the developing countries for undertaking reform commitments within their territories. For 
instance, manufacturing subsidy reforms in China has been a major agenda for the country (CTI, 
undated). However, in the recent period the US policies have been increasingly influenced by the 
domestic defensive compulsions. For instance, the pullout from Trans-Pacific Partnership (TPP) 
in 2017 (Helble, 2017) and the rhetoric even against the North American Free Trade Agreement 
(NAFTA) partners like Mexico (Deeds and Whiteford, undated) deserve mention. While the rising 
protectionism in US can be part explained by electoral politics, perceptions on prevalence of WTO-
incompatible trade policies in developing countries is another major driver (Lim, 2018). While the 
mindset change has been questioned within US (Lincicome, 2017), it is felt that the protectionist 
inclination would be in place there for some time.  
 
While the US has raised voice against policies of several trade partners (e.g., Mexico, Russia), 
its intervention on Chinese products has by far been most harsh. In June 2018, the US Trade 
Representative (USTR) announced increased tariff on a wide range of Chinese exports to US worth 
$50 billion. The trade war was further escalated with subsequent announcement on increased 
tariffs on Chinese imports worth another $200 billion. The covered items facing 25 percent duty 
include both low and high tech manufacturing products (USTR, 2018). In retaliation, the Chinese 
government imposed countermeasures, covering American exports of meat, seafood, grains, 
alcohol, tobacco etc. with a trade value of $60 billion, where the duties were increased between 5-
10 percent (DW, 2018). It is noted that continuation of such trade wars would lead to significant 
losses for countries subjected to such measures (Bouet and Laborde, 2017).  
 
In 2014 India has initiated a drive towards deepened industrialization (Make-in-India) by both 
attracting foreign multinationals to produce in India and by improving the Doing Business 
indicators and enabling the domestic players to participate in GVCs and IPNs. The sectors covered 
under this initiative includes both medium (e.g., food processing, leather, textile and garments) 
and high tech manufacturing sectors (e.g., auto-components, aviation, defense manufacturing, 
electronic and electrical machinery, pharmaceuticals). The country is also increasingly focusing 
for RTA route and newer opportunities for export promotion (Chakraborty, 2018). Therefore a 
prolonged trade war between China and US may provide Indian manufacturing exports a greater 
foothold in the US market for key manufacturing products.  
 
In this background, the current paper evaluates the possible opportunities for expanding Indian 
exports in the US market by bridging the possible gap emerging due to the trade war between the 
US and China. It is observed from Table 1 that the USTR tariff impositions on China are spread 
over 10 HS chapters. In the Table the count of products at disaggregated level under the 10 HS 
chapters are noted, along with the number of Indian export items. The third column shows the 
degree of commonality between the US measures on China and possible Indian export items. A 
higher number implies opportunities for Indian exports in US, as the corresponding Chinese 
products are witnessing higher import tariff against them. In the last column, the percentage share 
of India in world exports across the HS chapters are noted. 
 
                Source: Authors’ calculation based on Trade Map online database 
 
It is observed that for aircraft, spacecraft, and parts thereof (HS 88) and pharmaceutical products 
(HS 30) the ratio is 94 percent and 76 percent respectively, underlining the opportunities for India 
in US market in these segments. However, in case of pharmaceutical products India contributes 
Table 1: Count of Sanctioned Products 
HS 
Code Description 
Count of 
total Make 
in India 
Products 
Count of 
tariff-facing 
Chinese 
Products 
Percent of 
Affected 
Products 
(%) 
India’s Percent 
Share in World 
Exports (%) 
28 Inorganic chemicals 273 4 1.5 1.2 
29 Organic chemicals 1111 38 3.4 3.1 
30 Pharmaceuticals 59 45 76.3 2.5 
73 Articles of Iron and Steel 254 44 17.3 2.3 
76 
Aluminum and articles 
thereof 72 27 37.5 1.7 
85 
Electrical machinery and 
equipment 641 241 37.6 0.4 
86 Railway and locomotives 32 17 53.1 0.5 
87 
Vehicles and auto-
components 218 47 21.6 1.1 
88 
Aircraft, spacecraft, and 
parts thereof 17 16 94.1 1.2 
89 
Ships, boats and floating 
structures 22 11 50.0 2.9 
2.5 percent to world exports as compared to 1.2 percent in case of aircraft, spacecraft, and parts 
thereof. Therefore the current paper focuses on assessing opportunities for pharmaceutical 
products in the US market. The analysis is arranged along the following lines. The introduction is 
followed by a brief discussion on Make in India initiative for Pharma sector and US imports in the 
same sector respectively. Then through a few well-known trade indices, the competitiveness of 
India’s pharma exports to US is commented upon. Finally, based on the findings, certain policy 
conclusions are drawn. 
 
2. Make-in-India initiative in Wider Policy Context: Pharma Sector 
 
In 2004, India formed the National Manufacturing Competitiveness Council to promote the 
manufacturing sector competitiveness. In 2011, the ‘National Manufacturing Policy’ identified a 
number of sectors where through competitiveness enhancement India can deepen its presence in 
the world (GoI, 2011a). Subsequently, the need for enhancing manufacturing exports were 
explored through policy initiatives (GoI, 2011b). In continuation, the ‘Make in India’ scheme was 
introduced in 2014 to attract investments, encourage innovation, enhance skill level and make 
India a global hub of manufacturing activities. The initiative focusses on 25 key sectors, which 
include - automobiles, aviation, chemicals, IT & BPM, pharmaceuticals, construction, defense 
manufacturing, electrical machinery, food processing, textiles and garments, ports, leather, media 
and entertainment, wellness, mining, tourism and hospitality, railways, automobile components, 
renewable energy, biotechnology, space, thermal power, roads and highways and electronics 
systems (GoI, undated).  
 
It is observed that pharma sector is in the reckoning of the policymakers consistently as a major 
contributor to both value addition and exports. The notable initiative under the ‘Make in India’ 
programme in this sector are visible through – reduction of coronary Stents price by 85 percent, 
launching of Pharma Jan Samadhan and Pharma Sahi Daam, approval of 11 National Institutes of 
Pharmaceutical Education & Research (NIPERs) and so on (GoI, 2018). 
 
The pharma industry in India is 3rd largest in terms of volume and 10th largest in terms of value, 
thus contributing to around 10 percent of global production. The sector, which stood at US$ 16.4 
billion in 2016-17, has contributed to 6 per cent of the country’s total exports (IBEF, 2018). India 
is an exporter of both bulk drugs and formulations. It has also emerged as a major player in R&D 
services for global corporates, either through contracts or collaborative programmes (PWC, 2010). 
To facilitate technology transfer from abroad under Make in India, FDI in the pharmaceutical 
sector is allowed up to 100 percent through automatic route for manufacturing of medical devices. 
In addition, ‘Pharma Vision 2020’ has been introduced to make India a global leader in end-to-
end drug manufacture (IBEF, 2015), which would make India a drug discovery and innovation 
powerhouse through capacity creation at home. Focus is also given on encouraging indigenization 
of Active Pharmaceutical Ingredients (APIs) with a goal to lower their imports from China 
(ASSOCHAM, 2016). A concerted effort in this sphere is crucial because while the generic drug 
exports from the country is increasing, it’s reliance on China for import of raw materials is quite 
high (Kallummal and Bugalya, 2012). It has been noted that India’s global presence can be 
deepened further through coordinated policy efforts, namely - upgradation of quality systems, 
infrastructure creation, capability enhancement, move to create a brand for reliable, high-quality 
medicine supply, improving transparency and predictability of regulations and so on (FICCI, 
2015).  
 
Apart from the direct influence of the ‘Make in India’ initiative, the pharma sector has received 
support from other government programmes as well. India’s Foreign Trade Policy (2015-20) was 
launched in 2015 with the objective to boost exports and establish India as a major player in global 
trade by 2020. The introduction of Merchandise Exports from India Scheme (MEIS) under the 
FTP (2015-20), which intends to ensure the competitiveness of Indian exports in partner countries 
through incentives in terms of duty credit scrip, provided a major boost to the pharmaceutical 
sector (GoI, 2015). In addition, the ‘Make in India’ products are also entitled to public procurement 
policies (GoI, 2017). At the broader canvas, the FTP instruments integrate with the Make in India 
initiative and other regulatory reforms to improve Ease of Doing Business in India, and thereby 
intensify manufacturing activities and exports.  
 
3. Comparing Presence of China and India in US Pharmaceutical Imports 
 
According to IFPMA (2017), global pharmaceutical market is expected to reach USD 1.48 
trillion by 2021, growing from USD 1.10 trillion in 2016, which can be explained by market 
expansion in emerging countries and ageing population growth in the developed countries. The 
growth of the global brand medicines and generics sales are forecasted to reach USD 815-832 
billion and USD 495-505 billion respectively by 2021. It is observed from Trade Map data that in 
global import of pharmaceutical products (HS 30), US’s share has significantly increased from 
12.6 percent in 2013 to 17.2 percent in 2017. India on the other hand has emerged as one of the 
major exporters of generic drugs, accounting for 20 percent of the global demand. Indian medicines 
are now exported to almost all countries with US as the key market (IBEF, 2018). It is observed 
from Trade Map data that in global export of pharmaceutical products (HS 30), India’s share has 
increased marginally from 2.4 percent in 2013 to 2.5 percent in 2017.   
 
Figure 1: Percent share in US Pharma imports (by value)  
 
 
Source: Authors’ calculation based on Trade Map (ITC, undated) 
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Figure 1 shows the shares of India and China in US pharmaceutical imports over the last decade. 
It is observed that the penetration of India in US market for this category has been deeper as 
compared to China throughout the period. While the share of China has stagnated around 1.5 
percent since 2013, India has improved its share from a meagre 2.9 percent in 2008 to 6.5 percent 
in 2017, though over 2016-17 a drop in the same has been noticed. The graph indicates growing 
recognition and consequent demand for Indian pharma products in US market.  
 
Table 2 displays the share of China and India in US import of pharmaceutical products by HS 
headings (4-digit). It is observed that while China is a major player in dried glands and other organs 
(HS 3001), wadding, gauze, bandages and the like (HS 3005) and pharmaceutical preparations and 
products (HS 3006), Indian exports are mostly concentrated in medicaments consisting of mixed 
or unmixed products (HS 3004), medicaments consisting of two or more constituents mixed 
together (HS 3003) and pharmaceutical preparations and products (HS 3006). It is observed that 
India’s average shares in US imports of HS 3003, 3004 and 3006 have increased considerably 
during the recent period. In other words, a clearly demarked pattern of competitiveness of the two 
countries emerges from the US import analysis at the heading level.  
 
Table 2: US Imports by Value (USD 000 and Percent share) 
 
Description 
India China 
HS 
Code  
2008-12 2013-17 2008-12 2013-17 
3001 
Dried glands and other organs 
for organo-therapeutic uses etc. 
816 
(0.17) 
406 
(0.10) 
264772 
(56.28) 
176268 
(43.62) 
3002 
Human blood; animal blood 
prepared for therapeutic, 
prophylactic or diagnostic uses 
etc. 
6606 
(0.07) 
6629 
(0.37) 
23971.8 
(0.28) 
75099.2 
(0.42) 
3003 
Medicaments consisting of two 
or more constituents mixed 
together etc. 
27022 
(2.01) 
36443 
(4.01) 
36303.4 
(2.71) 
55192.8 
(6.07) 
3004 
Medicaments consisting of 
mixed or unmixed products etc. 
2625511 
(5.56) 
5782129 
(9.66) 
60943 
(0.12) 
269849 
(0.45) 
3005 
Wadding, gauze, bandages and 
the like 
195 
(0.02) 
4619 
(0.45) 
263320 
(34.62) 
391619 
(38.30) 
3006 
Pharmaceutical preparations and 
products 
4595 
(0.21) 
69132 
(2.70) 
168828 
(7.77) 
283980 
(11.10) 
Source: Authors’ calculation based on Trade Map (ITC, undated) 
                                  
4. Methodology and Data 
 
For the analysis, six well-known trade indices have been used for understanding India’s 
competitiveness in general and in the US market in particular, while comparing with the 
corresponding numbers for China. The following indices have been calculated at HS sub-heading 
level (6-digit). 
 
First, for understanding overall competitiveness of Indian exports, the Revealed Comparative 
Advantage (RCA) index has been computed by the following formula:  
 
𝑅𝐶𝐴𝑖 =
∑ 𝐴𝑖𝑋 / ∑ 𝐴𝑋
∑ 𝑊𝑖𝑋 / ∑ 𝑊𝑋
 
 
where, ∑ 𝐴𝑖𝑋 stands for export of a particular HS 6-digit product from country A (say, India), 
∑ 𝐴𝑋 stands for total exports from A, ∑ 𝑊𝑖𝑋 stands for exports of the product by all countries and 
∑ 𝑊𝑋 stands for total global exports. If the RCA index is higher than unity, then a country is said 
to possess comparative advantage in that product category. 
 
Second, for understanding whether Indian exports are increasingly moving towards a partner 
country, the Export Intensity Index (EII) has been computed by the following formula: 
 
𝐸𝐼𝐼𝐼𝑁𝐷,𝑗 =  
𝐼𝑁𝐷𝑗
𝑋 𝐼𝑁𝐷𝑊
𝑋⁄
𝑊𝑂𝑅𝑗
𝑋 𝑊𝑂𝑅𝑊
𝑋⁄
 
 
where, 𝐼𝑁𝐷𝑗
𝑋 stands for a particular HS 6-digit product from India to country j (say, US), 𝐼𝑁𝐷𝑊
𝑋  
stands for total exports of that product from India to all countries, 𝑊𝑂𝑅𝑗
𝑋 stands for total export 
of the HS 6-digit product from rest of the world to country j (or, import of the product by country 
j from rest of the world) and 𝑊𝑂𝑅𝑊
𝑋   stands for total global export of the HS 6-digit product (or, 
total global export of the HS 6-digit product). If the EII index for India in a product category is 
found to be greater than unity, then it is said to be having an intensive export relationship with that 
partner for that product. 
             
Third, for understanding whether Indian exports are indeed deepening their presence in the 
imports of a partner country, Revealed Trade Barrier (RTB) index has been computed by the 
following formula: 
 
𝑅𝑇𝐵𝑃𝐴𝑅𝑇,   𝐼𝑁𝐷 =  
𝑃𝐴𝑅𝑇𝐼𝑁𝐷
𝑀𝑖 𝑃𝐴𝑅𝑇𝐼𝑁𝐷
𝑀𝑇⁄
𝑃𝐴𝑅𝑇𝑊𝑂𝑅
𝑀𝑖 𝑃𝐴𝑅𝑇𝑊𝑂𝑅
𝑀𝑇⁄
 
 
where, 𝑃𝐴𝑅𝑇𝐼𝑁𝐷
𝑀𝑖  stands for imports of a particular HS 6-digit product by trade partner (say, US) 
from India, 𝑃𝐴𝑅𝑇𝐼𝑁𝐷
𝑀𝑇  stands for total imports by partner country from India, 𝑃𝐴𝑅𝑇𝑊𝑂𝑅
𝑀𝑖  stands for 
imports of the HS 6-digit product by partner country from rest of the world and 𝑃𝐴𝑅𝑇𝑊𝑂𝑅
𝑀𝑇  stands 
for total imports by partner country from rest of the world. In case the RTB index is greater than 
unity, it might be noted that India is not facing many trade barriers in import relationship in the 
partner country. EII and RTB taken together can be considered as a measure of competitiveness of 
a product in a partner country market.  
 
Fourth, in case there is both-way trade between India and the partner country in a HS 6-digit 
level product, the emerging specialization can be checked with the Export Specialization Index 
(ESI), computed by the following formula:   
 
𝐸𝑆𝐼𝑖𝑗 =  
𝐼𝑁𝐷𝑖𝑗
𝑋 𝐼𝑁𝐷𝑇𝑗
𝑋⁄
𝑃𝑅𝑇𝑖𝐼𝑁𝐷
𝑋 𝑃𝑅𝑇𝑇𝐼𝑁𝐷
𝑋⁄
 
 
where, 𝐼𝑁𝐷𝑖𝑗
𝑋 stands for exports of a particular HS 6-digit product from India to country j (say, 
US), 𝐼𝑁𝐷𝑇𝑗
𝑋  stands for total exports from India to partner country, 𝑃𝑅𝑇𝑖𝐼𝑁𝐷
𝑋  stands for exports of 
the particular product by partner country to India and 𝑃𝑅𝑇𝑇𝐼𝑁𝐷
𝑋  stands for total exports by partner 
country to India. In case the ESI index exceeds unity, India is said to be developing an export 
specialization with respect to the partner country. It can be confirmed by checking whether India’s 
export value is consistently greater than the corresponding import value, i.e., whether India enjoys 
a positive trade balance (TB) in that category.  
 
Finally, India’s nature of price competitiveness in a particular product category can be checked 
by computing the Unit Price Ratio (UPR) by the following formula: 
 
𝑈𝑃𝑅𝑖𝑗 =  
𝑈𝑉𝑖𝑗
𝑋
𝑈𝑉𝑖𝑗
𝑀 
 
where, 𝑈𝑉𝑖𝑗
𝑋 stands for the unit value of India’s exports of a particular HS 6-digit product to 
country j (say, US) and 𝑈𝑉𝑖𝑗
𝑀 stands for the unit value of India’s imports of that product from the 
partner country. If the UPR index exceeds unity, and India is enjoying positive trade balance as 
well as ESI greater than 1, it might occur due to better quality of Indian export, in line with the 
framework developed by Stiglitz (1987). Conversely, a UPR less than unity can coexist with 
positive trade balance and ESI greater than 1, if there is price competitiveness in favour of Indian 
exports. 
 
The data on trade values and unit prices for computing the indices used in the analysis has been 
accessed from the Trade Map database (ITC, undated). The last decade, i.e., 2008-17 has been 
considered as the period of analysis to identify the emerging trends, if any. In order to ensure that 
annual fluctuations do not influence the conclusions, five-year averages of the trade indices have 
been compared.  
 
5. Interpretation of Trade Indices 
 
The Indian competiveness scenario for the HS 6-digit codes under pharmaceuticals (HS 30) in 
both absolute and bilateral levels, are reported in Table 3. From the first set of columns, it is 
observed that the average RCA for only seven products has been consistently above unity over the 
two periods considered in the analysis. In other words, India is enjoying competitiveness in export 
of these products in global scale. Second, comparing the average EII and RTB indices for India 
with respect to the US market for the corresponding time periods, it can be seen that the indices 
for these products are also above unity. It can therefore be noted that, India may benefit in these 
product categories in the US market as a result of the importing country increasing tariff against 
China therein. These product categories are: Medicaments containing hormones or steroids used 
as hormones (HS 300339), Medicaments consisting of two or more constituents mixed together 
(HS 300390), Medicaments containing penicillins or derivatives thereof with a penicillanic acid 
structure (HS 300410), Medicaments containing antibiotics, put up in measured doses (HS 
300420), Medicaments containing provitamins, vitamins etc. (HS 300450), Medicaments 
consisting of mixed or unmixed products for therapeutic or prophylactic purposes (HS 300490) 
and Chemical contraceptive preparations based on hormones, prostaglandins, thromboxanes, 
leukotrienes etc. (HS 300660). As noted from Table 2, India already enjoys deepening presence in 
US market for the corresponding HS chapters.      
 Table 4 depicts the corresponding scenario for China. It is noted from the table that only for 
Opacifying preparations for x-ray examinations; diagnostic reagents for administration to patients 
(HS 300630), China enjoy an absolute competitiveness in global market (i.e., RCA greater than 
unity). The product group is observed to be enjoying bilateral competitiveness (i.e., both EII and 
RTB greater than unity) in the US market as well.  
 
Table 5 summarizes India’s bilateral competitiveness as reflected from the ESI, TB and UPR. 
It is seen that the first two conditions are favourable (i.e., ESI greater than unity, TB positive) for 
a total of nine product segments. The HS headings are – Extracts of glands or other organs or of 
their secretions, for organo-therapeutic uses (HS 300120), Medicaments containing antibiotics, not 
in measured doses or put up for retail sale (HS 300320), Medicaments containing insulin, not in 
measured doses or put up for retail sale (HS 300331), Medicaments containing hormones or 
steroids used as hormones (HS 300339), Medicaments consisting of two or more constituents 
mixed together (HS 300390), Medicaments containing penicillins or derivatives thereof with a 
penicillanic acid structure (HS 300410), Medicaments containing antibiotics, put up in measured 
doses (HS 300420), Medicaments containing provitamins, vitamins etc. (HS 300450) and 
Medicaments consisting of mixed or unmixed products for therapeutic or prophylactic purposes 
(HS 300490). Among the nine products, barring the exception of HS 300120 all other commodities 
have the UPR less than unity. In other words, India’s entry in the US market for these products 
might be backed by price competitiveness.  
 
The corresponding ESI, TB and UPR scenario for China has been shown with the help of Table 
6. It is observed that only for Medicaments containing antibiotics, not in measured doses or put up 
for retail sale (HS 300320), the competitiveness conditions (i.e., ESI greater than unity, TB 
positive) are getting fulfilled. The UPR for the product is less than unity, indicating possible price 
competitiveness therein.  
   
Combining the two lists emerging from Tables 3 and 5, it can be seen that India is enjoying 
clear advantage in six product categories in the US market, namely – Medicaments containing 
hormones or steroids used as hormones (HS 300339), Medicaments consisting of two or more 
constituents mixed together (HS 300390), Medicaments containing penicillins or derivatives 
thereof with a penicillanic acid structure (HS 300410), Medicaments containing antibiotics, put up 
in measured doses (HS 300420), Medicaments containing provitamins, vitamins etc. (HS 300450) 
and Medicaments consisting of mixed or unmixed products for therapeutic or prophylactic 
purposes (HS 300490). As noted from Table 2, India’s presence in US imports of HS 3003 and HS 
3004 are already substantial. Based on the evidence from the indices, it appears that China might 
not offer significant competition to India in these six product categories in US market.   
  
 Table 3: Trade Indices for India in Pharmaceutical Products (HS Code 30) 
HS Code 
Revealed Comparative 
Advantage Export Intensity Index Revealed Trade Barrier 
2008-12 2013-17 2008-12 2013-17 2008-12 2013-17 
300410 5.47 8.46 0.99 1.72 14.60 11.03 
300420 3.44 3.82 3.94 3.98 15.99 16.10 
300339 10.94 3.55 26.44 3.11 16.32 6.68 
300450 4.05 3.21 3.12 3.01 1.77 10.12 
300660 0.78 2.68 0.02 1.39 0.29 3.21 
300490 1.13 2.09 2.06 2.35 3.58 5.45 
300390 2.92 1.91 1.29 2.83 1.60 2.71 
300691 0.32 1.59 0.00 0.00 0.00 0.00 
300220 0.80 1.48 0.02 0.03 0.00 0.00 
300331 1.65 0.98 7269.83 2.04 22.52 0.20 
300320 5.98 0.98 1.17 0.45 0.81 1.07 
300670 0.77 0.95 1.06 0.05 0.01 0.00 
300431 0.65 0.88 1.79 0.69 0.01 0.00 
300120 0.76 0.55 5.57 22.77 2.54 1.31 
300610 0.29 0.34 0.07 0.12 0.04 0.11 
300630 0.06 0.20 0.33 0.44 0.00 0.21 
300439 0.25 0.20 0.99 1.04 0.81 0.76 
300290 0.38 0.19 0.49 0.60 0.20 0.08 
300640 0.23 0.16 1.17 1.33 0.09 0.03 
300230 0.13 0.13 0.05 0.35 0.05 0.01 
300432 0.04 0.12 0.00 0.52 0.03 0.42 
300510 0.12 0.09 0.12 0.10 0.01 0.00 
300620 0.05 0.03 4.75 0.00 0.20 1.37 
300212 0.00 0.00 0.00 0.00 0.00 0.00 
300215 0.00 0.00 0.00 0.00 0.00 0.00 
300449 0.00 0.00 0.00 0.00 0.00 0.00 
300219 0.00 0.00 0.00 0.00 0.00 0.00 
300211 0.00 0.00 0.00 0.00 0.00 0.00 
300213 0.00 0.00 0.00 0.00 0.00 0.00 
300214 0.00 0.00 0.00 0.00 0.00 0.00 
300341 0.00 0.00 0.00 0.00 0.00 0.00 
300342 0.00 0.00 0.00 0.00 0.00 0.00 
300349 0.00 0.00 0.00 0.00 0.00 0.00 
300360 0.00 0.00 0.00 0.00 0.00 0.00 
300441 0.00 0.00 0.00 0.00 0.00 0.00 
300442 0.00 0.00 0.00 0.00 0.00 0.00 
300460 0.00 0.00 0.00 0.00 0.00 0.00 
Source: Authors’ calculation based on Trade Map (ITC, undated) 
  
 Table 4: Trade Indices for China in Pharmaceutical Products (HS Code 30) 
HS Code 
Revealed Comparative 
Advantage Export Intensity Index Revealed Trade Barrier 
2008-12 2013-17 2008-12 2013-17 2008-12 2013-17 
300410 0.26 0.32 0.01 0.01 0.01 0.05 
300420 0.01 0.06 0.85 0.67 0.06 0.07 
300339 0.00 0.00 3.79 0.00 0.95 0.00 
300450 0.13 0.12 3.85 2.56 0.04 0.03 
300660 0.04 0.06 0.48 2.33 0.01 0.23 
300490 0.00 0.00 0.20 0.38 0.01 0.02 
300390 0.00 0.00 2.07 2.41 0.16 0.36 
300691 0.11 0.03 2.29 1.48 0.00 0.00 
300220 0.01 0.02 0.00 0.01 0.00 0.00 
300331 0.01 0.00 0.00 0.00 0.00 0.00 
300320 1.39 2.43 0.16 0.69 0.12 0.13 
300670 0.24 0.36 10.88 2.92 0.02 0.50 
300431 0.01 0.14 0.00 0.00 0.00 0.00 
300120 0.50 0.34 1.87 1.34 0.01 0.54 
300610 0.03 0.01 2.33 1.34 0.01 0.00 
300630 1.01 1.41 2.32 2.49 1.11 1.35 
300439 0.02 0.01 0.04 0.07 0.00 0.00 
300290 0.03 0.03 0.75 0.55 0.01 0.01 
300640 0.09 0.09 0.73 0.39 0.05 0.04 
300230 0.04 0.03 0.00 0.00 0.00 0.00 
300432 0.03 0.03 0.00 0.00 0.00 0.01 
300510 0.70 0.82 2.00 1.63 0.92 1.09 
300620 0.01 0.02 0.72 0.04 0.02 0.02 
300212 0.14 0.14 0.00 0.00 0.00 0.00 
300215 0.25 0.22 0.00 0.00 0.00 0.00 
300449 0.00 0.00 0.00 0.00 0.00 0.00 
300219 0.00 0.00 0.00 0.00 0.00 0.00 
300211 0.00 0.00 0.00 0.00 0.00 0.00 
300213 0.00 0.00 0.00 0.00 0.00 0.00 
300214 0.00 0.00 0.00 0.00 0.00 0.00 
300341 0.00 0.00 0.00 0.00 0.00 0.00 
300342 0.00 0.00 0.00 0.00 0.00 0.00 
300349 0.00 0.00 0.00 0.00 0.00 0.00 
300360 0.00 0.00 0.00 0.00 0.00 0.00 
300441 0.00 0.00 0.00 0.00 0.00 0.00 
300442 0.00 0.00 0.00 0.00 0.00 0.00 
300460 0.00 0.00 0.00 0.00 0.00 0.00 
Source: Authors’ calculation based on Trade Map (ITC, undated) 
  
 
   
Source: Authors’ calculation based on Trade Map (ITC, undated) 
  
Table 5:  Trade Indices for India in Pharmaceutical Products with USA (HS Code 30) 
HS Code 
Export Specialization Index Trade Balance Unit Price Ratio 
2008-12 2013-17 2008-12 2013-17 2008-12 2013-17 
300331 863.01 907.32 1551 265 0.00 0.03 
300339 174.59 34.87 45475 2764 0.05 0.08 
300450 13.72 14.61 27756 19440 0.27 0.14 
300410 5.61 7.11 26120 128829 0.40 0.37 
300230 7.37 5.73 -2286 -3022 0.93 0.95 
300420 5.53 5.30 219750 338724 0.23 0.35 
300691 0.79 5.23 -71 -537 0.33 1.79 
300120 3.24 3.56 77 1434 0.38 1.62 
300390 2.48 3.28 63834 59596 0.19 0.34 
300320 7.27 2.15 7581 233 0.23 0.74 
300490 1.02 1.64 1279701 3509898 0.06 0.15 
300670 3.52 1.57 -191 -1206 0.65 2.21 
300220 1.05 1.20 -12868 -25946 0.08 0.06 
300660 0.46 0.94 -42 60476 0.12 0.11 
300610 0.54 0.55 -3058 -5050 0.18 0.09 
300431 0.28 0.28 31558 32671 0.15 0.03 
300640 0.16 0.12 -1791 -2116 0.25 0.10 
300630 0.03 0.11 -439 1102 0.70 1.03 
300439 0.15 0.11 7027 4351 0.03 0.05 
300510 0.12 0.09 -1058 -2042 0.27 0.30 
300432 0.02 0.06 2 2631 0.07 0.04 
300290 0.14 0.05 -2884 -9927 0.07 0.18 
300620 0.16 0.05 -270 -1285 0.27 0.16 
300212 0.00 0.00 0 -4245 0.00 0.09 
300215 0.00 0.00 0 -4749 0.00 0.03 
300449 0.00 0.00 0 724 0.00 0.02 
300219 0.00 0.00 0 -1098 0.00 0.16 
300211 0.00 0.00 0 -254 0.00 0.01 
300213 0.00 0.00 0 -707 0.00 0.00 
300214 0.00 0.00 0 1 0.00 0.00 
300341 0.00 0.00 0 0 0.00 0.02 
300342 0.00 0.00 0 0 0.00 0.00 
300349 0.00 0.00 0 0 0.00 0.06 
300360 0.00 0.00 0 0 0.00 1.14 
300441 0.00 0.00 0 0 0.00 0.06 
300442 0.00 0.00 0 0 0.00 0.03 
300460 0.00 0.00 0 0 0.00 0.00 
 Table 6: Trade Indices for China in Pharmaceutical Products with USA (HS Code 30) 
HS Code 
Export Specialization Index Trade Balance Unit Price Ratio 
2008-12 2013-17 2008-12 2013-17 2008-12 2013-17 
300331 59.43 0.09 0 0 0.00 0.00 
300339 0.04 0.01 15 -86 0.01 0.02 
300450 0.45 0.53 -20877 -41272 0.15 0.12 
300410 0.27 0.26 -14556 173 0.13 0.13 
300230 2.23 1.31 -61260 -176908 0.53 0.60 
300420 0.22 0.20 -102890 -124679 0.10 0.10 
300691 0.25 0.11 -71 -537 0.56 0.60 
300120 2.13 2.11 651 -242 1.27 7.86 
300390 0.22 0.40 -15474 44621 0.18 0.27 
300320 2.35 5.44 1928 10225 0.11 0.09 
300490 0.04 0.05 -372115 -828073 0.04 0.05 
300670 1.01 0.59 -363 -1644 0.36 0.59 
300220 0.01 0.01 -46301 -58580 0.16 0.12 
300660 0.01 0.02 791 14763 0.33 0.33 
300610 0.07 0.02 -44749 -117101 0.08 0.05 
300431 0.00 0.05 -138344 -26491 0.51 0.52 
300640 0.06 0.07 -1840 -11838 0.22 0.13 
300630 0.51 0.79 165895 319813 1.25 1.85 
300439 0.01 0.01 -63969 -103043 0.06 0.07 
300510 0.66 0.76 44887 59704 0.36 0.42 
300432 0.01 0.02 -1412 -2052 0.03 0.03 
300290 0.01 0.01 -6254 -28198 0.18 0.09 
300620 0.02 0.04 -3525 -17033 0.01 0.01 
300212 0.00 0.00 0 -131239 0.00 0.05 
300215 0.00 0.00 0 -175231 0.00 0.01 
300449 0.00 0.00 0 -3302 0.00 0.01 
300219 0.00 0.19 0 -8305 0.00 0.02 
300211 0.00 0.00 0 -14 0.00 0.00 
300213 0.00 0.00 0 -142 0.00 0.00 
300214 0.00 0.00 0 -63 0.00 0.00 
300341 0.00 0.00 14 78 0.00 0.00 
300342 0.00 0.00 14 78 0.00 0.00 
300349 0.00 0.16 0 0 0.00 0.02 
300360 0.00 0.03 0 0 0.00 0.05 
300441 0.00 0.00 -3585 -4846 0.00 0.00 
300442 0.00 0.00 -3585 -4846 0.00 0.00 
300460 0.00 2.53 0 9 0.00 0.03 
 Source: Authors’ calculation based on Trade Map (ITC, undated) 
 
 
  
6. Conclusion 
 
One crucial objective of the Make in India initiative has been to attract foreign firms to establish 
production facility in India and transfer modern technology, so that domestic firms also benefit 
from the spillover effect in long run. The other goal is to reduce import dependency and enhance 
domestic production throughout the value chain, ensuring maturity of the Indian players in the 
process. For facilitating the process in manufacturing sector in general and pharma sector in 
particular, a number of steps has been undertaken in the last couple of years (GoI, 2018). Though 
India offer a growing domestic market to facilitate Make in India scheme, export promotion would 
play a crucial role in realization of both the objectives. It is therefore imperative that India is able 
to extract the benefits of appropriate opportunities in trade arena, and the recent US tariff 
imposition on China offer India one such occasion.  
 
The analysis however portrays a modest opportunity for Indian pharmaceutical exports in the 
US market, based on their past performance. Only six products, based on the six indicators, are 
found to be enjoying competitiveness in the US market. The result can be part explained by the 
fact that Chinese and Indian pharma exports are entering US market in demarked product 
categories (Table 2). Nevertheless, the results reflect modestly on absolute performance of Indian 
pharma exports in the US market so far, despite greater focus on the sector in recent period. The 
scenario therefore pose a crucial challenge for Indian pharma sector. The modest performance 
expectation might be shaped by two broad factors. First, the Indian exports are intensive in generic 
products, rather than patented medicines. The scenario is not expected to change drastically, given 
the modest R&D scenario prevailing in pharma sector (Joseph, 2011). Government incentives to 
facilitate research in the pharma sector might play a crucial role in this regard. Second, though 
Indian firms have adopted the Good Manufacturing Practices (GMP) guidelines, compliance with 
the evolving standards set by US Food and Drug Administration (USFDA) would continue to play 
a crucial role. Many Indian products, including medicine items, have been rejected by USFDA 
over the last decade (ET, 2016; Phadnis, 2017). Therefore, developing a framework to ensure 
standard equivalence with US would be important in enhancing Indian pharma exports.       
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